Key result
AMI critical pathway linked to ~62% lower odds of delayed door-to-balloon time.
Why the study?
The impact of implementing a critical pathway on acute myocardial infarction quality indicators needed to be determined.
Does the implementation of a critical pathway improve door-to-balloon time and discharge medication prescription rates in patients undergoing primary angioplasty for AMI?
Observational (n=175)
No
Does the implementation of a critical pathway improve door-to-balloon time and discharge medication prescription rates in patients undergoing primary angioplasty for AMI?
Implementation of a critical pathway for AMI significantly reduces door-to-balloon time and increases the prescription of guideline-directed medical therapies at discharge.
Answers are grounded in this paper and cite their sources.
May reduce door-to-balloon time and boost discharge prescriptions; hypothesis-generating for critical pathways and requires randomized confirmation before practice change.
Study Objective. To determine the impact of a critical pathway on acute myocardial infarction (AMI) quality indicators. Design. Retrospective chart review. Setting. Large university hospital. Patients. One hundred seventy‐five patients who underwent primary percutaneous transluminal angioplasty for AMI (control group 89 patients, intervention group 86 patients). Measurements and Main Results. The medical records of the control group (1998–1999) were reviewed for door‐to‐balloon (DtB) time (the time between the patient's arrival at the emergency department and the first balloon inflation during a percutaneous transluminal coronary angioplasty procedure). Drug therapy prescribed at hospital discharge (aspirin, β‐blocker, angiotensin‐converting enzyme [ACE] inhibitor, and lipid‐lowering therapy) was also reviewed. The data collected for the control group were compared with the intervention group data (2000–2001). The impact of the pathway was evaluated using the Wilcoxon rank sum test, odds ratios (ORs), and χ 2 tests. The DtB time was significantly lower in the intervention group versus the control group (91.5 vs 108 min, p<0.01), and fewer intervention patients exceeded the guidelines with a DtB time longer than 120 minutes (OR 0.38, p<0.01). In addition, the intervention group was more likely than the control group to be prescribed an ACE inhibitor (OR 3.7, p<0.01) or lipid‐lowering therapy (OR 3.7, p=0.02) at discharge. Aspirin and β‐blockers were not prescribed differently in the intervention versus control groups (aspirin 95.2% vs 96.2%, β‐blockers 93.5% vs 92.6%). Conclusion. These data suggest that in the current era of published treatment guidelines, implementation of a critical pathway can further improve AMI quality indicators and clinical care.
No takes yet. Share an insight, caveat, or question.
Bestul et al. (2004) conducted an observational in Acute myocardial infarction (n=175). Critical pathway vs. Historical control group prior to pathway implementation (1998-1999) was evaluated on Door-to-balloon (DtB) time and exceeding guidelines for DtB time > 120 minutes (OR 0.38, p=<0.01). A critical pathway for AMI lowered door-to-balloon time and increased discharge ACE inhibitor and lipid-lowering prescriptions.
Synapse has enriched 10 related papers. Consider them for comparative context: